Acquiring Company
LumiThera
Acquired Company
MacuLogix, Inc.
PoulsboGeorgiaInformation TechnologyHealthcareHealth CareHealthcareDescription
LumiThera Inc., a commercial stage medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the purchase of MacuLogix assets by its wholly owned subsidiary. MacuLogix, Inc., is the leader in early diagnosis of dry Age-related Macular Degeneration (AMD) patients and developer of the wearable AdaptDX Pro® dark adaptometer. The device allows eye care professionals to measure dark adaptation, which is used to diagnose dry AMD in patients earlier than any other technology. The AdaptDx Pro, launched in 2020, is available for sale in the US, Canada, EU and other countries.
Who to call at LumiThera, and when
When LumiThera changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day LumiThera raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at LumiThera, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at LumiThera. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment LumiThera makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired MacuLogix, Inc.?
MacuLogix, Inc. was acquired by LumiThera, based in Poulsbo. The deal was reported on July 26, 2022. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. LumiThera is privately held and operates in Information Technology.
When did LumiThera acquire MacuLogix, Inc.?
LumiThera's acquisition of MacuLogix, Inc. was reported on July 26, 2022. LumiThera Inc., a commercial stage medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the purchase of MacuLogix assets by its wholly owned subsidiary. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does MacuLogix, Inc. do?
MacuLogix focuses on detecting and tracking age-related macular degeneration (AMD). It is privately held, operating in Healthcare, and is based in Georgia.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.